Travere Therapeutics Shares Rise 40.8% Following FDA Approval of Filspari
Travere Therapeutics (TVTX) shares surged 40.8% after the FDA approved Filspari for treating focal segmental glomerulosclerosis (FSGS) in patients aged 8 and above. The approval follows a successful phase 3 study showing a 46% reduction in proteinuria, outperforming the 30% reduction from irbesartan. The drug is the first FDA-approved treatment for FSGS.
Tickers: $TVTX
Topics: FDA approval FSGS treatment pharmaceuticals rare diseases stock price movement